Ionis Pharmaceuticals, Inc. (IONS)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012
TRYNGOLZA Revenue	113.60M	107.50M	-
DAWNZERA Revenue	-	7.80M	-
Total Product Revenue	163.80M	115.30M	-
SPINRAZA Royalties Revenue	207.20M	212.30M	216.10M
WAINUA Royalties Revenue	56.40M	49.10M	20.20M
Other Royalties Revenue	24.70M	35.00M	34.20M
Commercial Licensing and Other Royalty Revenue	5.50M	24.10M	22.60M
Total Commercial Revenue	483.20M	435.80M	293.10M
Amortization from Upfront Payments Revenue	-	-	131.40M
Milestone Payments Revenue	-	-	106.40M
R&D License Fees Revenue	-	-	71.30M
Other R&D Services Revenue	-	-	23.50M
Collaborative Agreement Revenue	337.80M	465.80M	332.60M
WAINUA Joint Development Revenue	53.10M	42.10M	79.40M
Total R&D Revenue	390.90M	507.90M	412.00M
Revenue (Other)	-611.11M	-672.29M	-432.16M
Revenue (Total)	874.09M	943.71M	705.14M

Data Source: Fiscal.ai Last updated: Jul 29, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 9, 2026

Data Sources Report a data error